These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 27101528)
1. Histiocytic neoplasms in the era of personalized genomic medicine. Durham BH; Diamond EL; Abdel-Wahab O Curr Opin Hematol; 2016 Jul; 23(4):416-25. PubMed ID: 27101528 [TBL] [Abstract][Full Text] [Related]
2. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875 [TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403 [TBL] [Abstract][Full Text] [Related]
4. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847 [TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. Durham BH Semin Cell Dev Biol; 2019 Feb; 86():62-76. PubMed ID: 29526544 [TBL] [Abstract][Full Text] [Related]
6. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations. Tran G; Huynh TN; Paller AS J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340 [TBL] [Abstract][Full Text] [Related]
7. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436 [TBL] [Abstract][Full Text] [Related]
8. Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Ozkaya N; Dogan A; Abdel-Wahab O Hematol Oncol Clin North Am; 2017 Aug; 31(4):705-719. PubMed ID: 28673397 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]
10. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Go H; Jeon YK; Huh J; Choi SJ; Choi YD; Cha HJ; Kim HJ; Park G; Min S; Kim JE Histopathology; 2014 Aug; 65(2):261-72. PubMed ID: 24720374 [TBL] [Abstract][Full Text] [Related]